Long-term use of tirzepatide shows sustained and significant weight loss in adults with overweight or obesity.

Lilly's announcement that it would make its experimental weight-loss pill in the U.S. comes amid administration pressure on ...

As GLP-1s quiet the constant hum of hunger, are they a permanent pharmaceutical crutch, or can they create space to let us ...

A Monell Chemical Senses Center study published this week in the Journal of Clinical Investigation offers renewed hope for ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal ...

Both GLP-1 receptor agonists and SGLT2 inhibitors linked to reduced risk for ADRD, with no significant difference between them.

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Ozempic is not marketed as a weight loss drug and is prescribed to those with type 2 diabetes to help manage their condition ...

A groundbreaking study published in the journal Current Neuropharmacology highlights a concerning potential link between Glucagon-like Peptide-1 (GLP1) receptor agonists-widely used in blockbuster ...

The drug helped lower patients’ blood sugar and reduce their weight by an average of 16 pounds.

Injectables for type 2 diabetes and weight loss could soon be a thing of the past. Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule ...